These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24166902)

  • 1. Conjunctival melanomas harbor BRAF and NRAS mutations--Letter.
    Weber JL; Smalley KS; Sondak VK; Gibney GT
    Clin Cancer Res; 2013 Nov; 19(22):6329-30. PubMed ID: 24166902
    [No Abstract]   [Full Text] [Related]  

  • 2. Conjunctival melanomas harbor BRAF and NRAS mutations--response.
    Griewank KG; Westekemper H; Schilling B; Livingstone E; Schimming T; Sucker A; Hillen U; Steuhl KP; Zimmer L; Schadendorf D
    Clin Cancer Res; 2013 Nov; 19(22):6331-2. PubMed ID: 24170549
    [No Abstract]   [Full Text] [Related]  

  • 3. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
    Valentín-Bravo FJ; Pérez-Rodríguez Á; García-Álvarez C; García-Lagarto E; Saornil-Álvarez MA
    Arq Bras Oftalmol; 2023; 86(5):e20230071. PubMed ID: 35544941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
    Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.
    Mikkelsen LH; Larsen AC; von Buchwald C; Drzewiecki KT; Prause JU; Heegaard S
    APMIS; 2016 Jun; 124(6):475-86. PubMed ID: 27004972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma.
    Djulbegovic MB; Uversky VN; Harbour JW; Galor A; Karp CL
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 11. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.
    Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309
    [No Abstract]   [Full Text] [Related]  

  • 12. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 14. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
    Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.
    Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J;
    J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122
    [No Abstract]   [Full Text] [Related]  

  • 17. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
    Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
    [No Abstract]   [Full Text] [Related]  

  • 18. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
    Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
    J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Murine Model for Metastatic Conjunctival Melanoma.
    de Waard NE; Cao J; McGuire SP; Kolovou PE; Jordanova ES; Ksander BR; Jager MJ
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2325-33. PubMed ID: 25722211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.